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haematological treatments 
 
 
Abstract: 
 
Introduction: Self-renewal is considered a defining property of stem cells. Self-renewal is essential in 
embryogenesis and normal tissue repair and homeostasis. However, in cancer, self-renewal 
pathways, e.g. WNT, NOTCH, Hedgehog and BMP, frequently become de-regulated in stem cells, or 
more mature progenitor cells acquire self-renewal properties, resulting in abnormal tissue growth 
and tumorigenesis. 
 
Areas Covered: This review considers the conserved embryonic self-renewal pathways, including 
WNT, NOTCH, Hedgehog and BMP. The article describes recent advances in our understanding of 
these pathways in leukaemia and, more specifically, leukaemia stem cells (LSC), how these pathways 
cross-talk and interact with the LSC microenvironment, and discusses the clinical implications and 
potential therapeutic strategies, both preclinical and in clinical trial for haematological malignancies. 
 
Expert Opinion: The conserved embryonic self-renewal pathways are frequently de-regulated in 
cancer stem cells (CSC), including LSCs. There is significant cross-talk between self-renewal 
pathways, and their downstream targets, and the microenvironment. Effective targeting of these 
pathways is challenging due to cross-talk, and importantly, because these pathways are important 
for normal stem cells as well as CSC, adverse effects on normal tissues may mean a therapeutic 
window cannot be identified. Nonetheless, several agents targeting these pathways are currently in 
clinical trials in haematological malignancies. 
(200 words) 
 
Article Highlights: 
 
 Self-renewal pathways, including WNT, NOTCH, Hedgehog and BMP are frequently de-
regulated in haematological malignancies 
 There is significant cross-talk between self-renewal pathways and their downstream targets 
 Self-renewal pathways remain active in normal tissues and are important for tissue repair, and 
often targeting these conserved embryonic self-renewal pathways results in toxicity to normal 
cells in vitro and significant side effects in patients 
 Small molecule inhibitors targeting the NOTCH and Hedgehog pathways are being used 
clinically in some solid tumours (e.g. breast cancer and basal cell carcinoma, respectively) and 
are in clinical trial in haematological malignancies 
 SMO inhibitors, which target the Hedgehog pathway have recently shown some promise in 
acute myeloid leukaemia and myelofibrosis 
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1. Introduction: 
Cancer stem cells (CSC) offer the concept that a small population of cells sharing characteristics of 
differentiation, self-renewal and homeostatic control, allow for the maintenance and dissemination 
of disease [1, 2].  Within haematological disease, these are referred to as leukaemic stem cells (LSCs).  
LSCs are mostly quiescent, in G0-phase and out of the cell cycle, and home to the bone marrow 
microenvironment, in which they are protected from apoptosis and conventional treatments [3-5].  
Within a variety of haematological malignancies, including acute myeloid leukaemia (AML) [6], chronic 
myeloid leukaemia (CML) [5, 7], and multiple myeloma [8], the existence of LSCs has been identified.  
In vivo and in vitro experimental models have demonstrated that LSCs share many features with 
haemopoietic stem cells (HSCs) [9], including self-renewal and engraftment potential, but have also 
offered critical differences in functional properties [10], which allows for a therapeutic index of 
intervention, that would permit targeting of LSCs, whilst maintaining normal haematopoiesis.  
 
AML LSCs were one of the first CSC populations to be characterised within haematological and solid 
malignancy [6, 11].  The complexity in morphological, genetic, and epigenetic heterogeneity within 
AML makes identifying an appropriate therapeutic target challenging, but may allow for LSC 
characterisation if the AML LSCs have distinct features according to their subtype.  However, the 
immunophenotypic identification of the AML LSC remains a persistent area of debate [6, 12-14].  
Historically, LSCs (both in AML and CML) have been characterised within the CD34+CD38- population, 
where their presence has been shown to be capable of generating leukaemic primary, secondary and 
tertiary engraftment in non-obese diabetic severe combined immunodeficient mice [6, 11].  However, 
recent studies have suggested that LSC activity can extend into the CD34+CD38+ population, with data 
indicating that leukaemia-initiating capacity could be present in a mature CD34- population [15, 16].  
This suggests that LSCs can either be derived from HSCs or from progenitor cells that acquire self-
renewal properties.  Additional markers of AML LSCs have been proposed, including CD123 [17, 18], 
CD33 [18], CD45RA [19], CD47 [20], CD96 [21], and CD93 [22].  To date, none have been translated 
into the clinical setting for identification or targeting of the LSC.  This is, in part, due to the intra-patient 
and inter-patient heterogeneity identified within AML LSC populations [16, 23] and has been 
particularly noted within relapse, where AML LSC frequency and phenotypic diversity has been shown 
to be much greater compared to the initial diagnostic LSC [24, 25].   
 
Regardless of these complexities, the importance of AML LSCs clinically is well established.  Most 
pertinently, within the identification of minimal residual disease (MRD), which resembles that of the 
diagnostic disease population, allows response to therapy to be followed over time, and offers a 
prognostic indicator for adverse outcome [26, 27].  It seems reasonable that LSCs reside within this 
population, having only been minimally impacted by conventional chemotherapy that targets dividing 
cells, and therefore, it stands that treatments focussing on the elimination of LSCs will reduce MRD 
and ultimately improve disease outcomes.  Furthermore, it has been shown that AML patients with a 
greater number of LSCs or a more prevalent stem cell phenotype at diagnosis have inferior clinical 
outcomes compared to those who have fewer LSCs or a less prevalent stem cell phenotype [23, 28]. 
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Although the most historic evidence of LSCs within haematological disease arise within AML, much 
insight into potential therapeutic strategies can be acquired from CML, where the chronic-phase 
disease represents a classic example of the stochastic CSC hypothesis model, without the molecular, 
epigenetic and genetic heterogeneity seen within AML.  Furthermore, it is known that as the disease 
progresses to the acute phase, termed blast crisis (BC), committed progenitors gain self-renewal 
function; again highlighting the potential for LSC to be derived from a more mature progenitor 
population [29-31].  Therefore, understanding the LSC in CML may be clinically transferable to other 
stem cell driven diseases, including AML.  
 
In CML, low-level BCR-ABL positive LSCs, as defined within a CD34+CD38- population, have been 
identified in the bone marrow of tyrosine kinase inhibitor (TKI)-treated CP-CML patients in deep 
molecular response (i.e. those that achieve a 4-log or greater reduction of quantitative BCR-ABL 
expression from standardised baseline over a prolonged period) [32-35].   These cells have been shown 
to be capable of growth in long-term culture-initiating cell (LTC-IC) assays and have murine 
engraftment potential, demonstrating their self-renewal capability.  The demonstration that CML LSCs 
persist in the presence of a targeted therapy demonstrates the phenomenon of disease persistence, 
and highlights that LSCs are BCR-ABL independent, relying on other pathways to sustain their survival 
[36, 37].  The concept of disease persistence through quiescent LSCs has been further highlighted in 
recent years by trials exploring the discontinuation of TKIs in CP-CML patients with sustained deep 
molecular response [38-41].  These trials have demonstrated that discontinuation of therapy can be 
selectively achieved, with the most recent update of the ‘Stop IMatinib’ (STIM) trial data stating the 
cumulative incidence of molecular relapse at 60 months was 61% (CI 52-57%), with few cases of late 
relapse being observed [42].  This suggests that if molecular relapse is to occur, it happens early.  It 
seems reasonable then, that targeting both the LSC population and BCR-ABL will lead to superior 
curative potential within CML.  
 
A number of challenges remain within both the scientific and clinical communities in the eradication 
of LSCs, in both AML and CML.  Firstly, in the identification of an appropriate specific target, or pan-
target, that will enable eradication of the LSCs without a transient response.  Secondly, when an 
appropriate target is identified that is clinically justifiable, the timings of intervention must be 
deduced, as well as the evaluation of disease persistence.  This will remain a huge clinical challenge, 
especially in view that therapies that are only effective against the stem cell compartment (which 
represents 1-2% of bulk) may be difficult to evaluate due to the persistence of bulk malignant cells 
and concordant chemotherapy-based treatment.  This review aims to evaluate scientific and clinical 
approaches for targeting self-renewal pathways in LSCs.   
 
2. Signalling pathways as a target for LSC eradication 
 
As discussed, self-renewal is considered to be the integral property of the LSC, and its deregulation is 
known to affect the development, maintenance, and persistence of LSCs in both AML and CML.   To 
date, a number of aberrant signalling pathways have been proposed to contribute to the LSC 
phenotype [43-47].  These pathways, including hedgehog, Notch and Wnt, are known regulators of 
cell survival, and are often differentially expressed following genetic events.  A number of deregulated 
proteins within these pathways may represent a broadly applicable therapeutic strategy, however, it 
is well known that these pathways rarely work in isolation, and rely on a web of activity leading to 
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disease maintenance, persistence, and progression.  The complexities in interaction between these 
pathways are well documented and will be discussed within each heading below (figure 1).  To add to 
this complexity in AML is the genetic variation that is seen, as this can mediate the proliferative and 
anti-apoptotic signals.   Expression of specific oncogenes, such as FLT3, RAS, and MLL, may create new 
dependencies on specific signalling pathways in LSCs, and activate signalling pathways in isolation or 
simultaneously [48, 49].  Therefore, developing a therapeutic intervention that is efficacious in all 
activated pathways remains unachievable.  Our best option remains to understand the acquired 
vulnerability in the mechanisms of the signalling pathways, which may offer a therapeutic window to 
eradicate the LSCs and plan for clinical translation.  
 
3. Evolutionary conserved self-renewal pathways 
Hedgehog signalling 
The Hedgehog (Hh) signalling pathway has been shown to be inappropriately activated in a number of 
malignancies, including AML and CML, where it is intrinsically involved in the maintenance and 
expansion of the LSC compartment [50-52].  The Hh signalling pathway is an evolutionary conserved 
signalling pathway that is critical for embryonic development and adult homeostasis [53, 54].  Within 
haematological malignancy, activation of the pathway has been shown to be linked to primary 
immotile cilia [55, 56], where the receptor-ligand interaction causes the internalisation of PTCH1 and 
subsequent activation of Smoothened (SMO).  This enables SMO to move into the cilium allowing for 
the accumulation of the active forms and the activation of key downstream targets [57].  SMO is the 
critical mediator in the canonical pathway and, therefore, represents a key therapeutic target to 
prevent the pathway’s activation. SMO can be readily targeted with pharmacological agents, including 
cyclopamine, and clinical grade agents, such as LDE225 (sonidegib) [58] or PF-04449913 (glasdegib) 
[57, 59]. 
 
However, the pathway’s complexity lies in its interactions and dependency with other key survival 
pathways.  It has been suggested that the survival of CML progenitor cells is maintained by both the 
auto-activation of Hh and β-catenin [60].  Furthermore, Hh activation modulates NUMB-p53 
responses, therefore, Hh suppression will subsequently alter p53 target genes; p53 is referred to as 
the guardian of the genome, therefore, careful evaluation of modulation of its function needs to be 
gained [61, 62].  p53 as a modulatory target in leukaemia is an area which is becoming of increasing 
interest; both in CML [63] and AML [64]. 
 
The importance of Hh signalling in CML is well established, with SMO inhibition leading to reduced 
self-renewal capacity of CML LSCs in both in vitro models with clinical grade SMO antagonists, and in 
vivo¸ where Smo-deficient mice have reduced leukaemogenesis in primary and secondary 
transplantation models [50, 52, 58].  Furthermore, combination of SMO antagonists with TKIs has been 
demonstrated to lead to a synergistic reduction of chronic phase (CP) CML LSCs in patient samples in 
vitro and CP and BC CML xenograft transplantation models [58, 65].  Our group has recently 
demonstrated that LDE225, a small molecule clinically investigated SMO inhibitor, used alone and in 
combination with the TKI, nilotinib, inhibited the Hh pathway in CD34+ CP-CML cells, reducing the 
number and self-renewal capacity of CML LSC in vitro [58].  The combination had no effect on normal 
HSCs and when combined, these agents reduced CD34+ CP-CML cell engraftment in NSG mice.  
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Furthermore, upon administration to EGFP+/SCLtTA/TRE-BCR-ABL mice, the combination enhanced 
survival with reduced leukaemia development in secondary transplant recipients.   
Importantly, deregulation of Hh may potentially contribute to disease progression, with differential 
Hh activity increasing as CML progresses to BC [60], and increased gene expression of PTCH1 has been 
observed in BC samples [46].  Therefore, early targeting of the pathway may be therapeutically viable 
to reduce disease progression. 
Whilst preclinical data appears promising to support the Hh pathway as a therapeutic target in CML, 
clinical trials utilising SMO antagonists as a therapeutic option have halted in early phases. Within solid 
tumors, these inhibitors have successfully been translated into clinical practice [66, 67], however, 
within CML when combined with TKI, toxicity has been a major limitation [68, 69].   
In AML, the role of Hh has not been fully elucidated, with limited data available on the implications of 
Hh deregulation on disease biology, perhaps due to the vast heterogeneity seen within the disease.  
Activation of Hh, through SMO and GLI expression, has been described within primary AML samples, 
particularly acute promyelocytic leukaemia (APML) [70, 71]; no SMO mutations have been identified 
to account for this increase in activity [55].   It is clear, however, that there is a prognostic significance 
in its expression, with increased GLI1 and GLI2 being associated with reduced overall survival and as a 
marker of prognosis, respectively [72].  
Studies suggest that HHIP, a membrane-associated or soluble glycoprotein that functions to bind Hh 
ligands, can suppress leukaemic cell proliferation [73]; furthermore, within the same study, reduced 
stromal HHIP expression was shown to contribute towards the development of AML.   HHIP can be 
modulated through standard chemotherapy agents, where it has been demonstrated that 5-
azacitadine-mediated amplification of stromal cell HHIP expression led to attenuated leukaemic cell 
proliferation potential. 
The biological significance of pathway modulation has yet to be fully understood, with varying results 
available.  Genetic inactivation of SMO in MLL-AF9-transformed LSCs does not affect AML 
development in primary recipient mice [74].  Conversely, SMO inhibition with cyclopamine has been 
shown to reduce proliferation in myelomonocytic cell lines [55].  AML, as a disease, shows great 
heterogeneity and, therefore, focused evaluation through each of the classified disease entities needs 
to be undertaken, but it appears that there may be a therapeutic role for Hh inhibitors within a 
myelomonocytic phenotype.  It is more clear that pharmacologic inhibition of Hh signalling appears to 
enhance AML ‘gold-standard’ therapy by sensitising LSCs to chemotherapy within the bone marrow 
microenvironment [75], which may lead to clinical advances in the eradication of AML LSCs.  Currently, 
clinical trials are under way to investigate Hedgehog inhibitors in AML, and early phase 1/2 results 
appear promising [59, 76]. Of note, a subsequent phase 2 clinical trial of LDE225 in AML, 
NCT01826214, recently closed due to lack of efficacy as a single agent; perhaps highlighting the limited 
activity of SMO inhibition on bulk disease.  
Wnt signalling 
The Wnt signalling pathway plays an essential role in the maintenance and differentiation of LSCs and 
the propagation of malignancies [29, 77].  Its activation has been demonstrated in acute disease, 
namely AML LSCs and within myeloid BC CML [29, 78].  Furthermore, it has been suggested that a 
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deletion within β-catenin reduces the ability of mice to develop Bcr-Abl positive leukemias, which is 
suggestive of a role in the pathogenesis of chronic disease [47].  Therefore, targeting Wnt is a viable 
option in eradication of the LSC and in the prevention of disease progression and dissemination.   
Within CML, loss of β-catenin in a murine model of CML impaired the development of the disease by 
inhibiting LSC self-renewal, and genetic and pharmacological inhibition of β-catenin activity synergised 
with TKI to target the loss of CML LSCs [29, 79].  CBP/catenin antagonists have demonstrated efficacy 
in eliminating the CML and acute lymphoblastic leukaemia (ALL) LSC population in vitro and in vivo  
[80, 81]. A similar importance is seen within AML, where high expression of Ctnnb1 has been reported 
to correlate with poor prognosis [82].  Deletion of β-catenin within murine models has been shown to 
significantly reduce development and transplantation of AML driven by MLL-AF9 or HoxA9 [83, 84].  
In turn, within murine models of MLL-rearrangement AML it has been shown that self-renewal of LSCs 
is mediated, in part, by Ctnnb1, suggesting that Ctnnb1 may represent a therapeutic target within this 
subtype.  Genetic and pharmacological inhibition of Ctnnb1 leads to decreased leukaemia formation.  
Interference with prostaglandin signalling has been shown to target the Wnt/β-catenin axis in HSCs 
[85], and treatment with COX inhibitors, such as indomethacin, has been shown to lead to a decrease 
of LSCs in secondary recipients [83].  This is mediated through Ctnnb1, although translating this 
clinically would be a challenge in view of adverse risk of bleeding.  Inhibitors of canonical Wnt signalling 
are currently undergoing phase I clinical trials in AML (NCT01398462) [86].  
Again, the interactions with other survival pathways, complicates antagonising Wnt/β-catenin.  For 
example, within CML, TKI exposure has been shown to upregulate CD27 signalling, resulting in 
activation of Wnt target genes, which include Notch and c-Myc [87, 88].  Wnt-Notch interaction is well 
documented, particularly within the bone marrow microenvironment, where mutations of Ctnnb1 
have been found in osteoblasts resulting in overexpression of Notch ligands and activation of the 
Notch pathway in HSCs [89]. 
The non-canonical Wnt (i.e. β-catenin independent) signalling pathways are diverse and can be 
initiated by WNT interaction with Frizzled receptors, or RYK and ROR receptor tyrosine kinases, to 
regulate small GTPases, as well as calcium flux and kinase cascades [90].  This area is not as well 
characterised in LSC maintenance as the canonical pathway [91]. Non-canonical signalling has been 
shown to exert an antagonistic effect on canonical signalling, with Wnt5a promoting GSK3β 
independent degradation of β-catenin and competing with Wnt3a for binding to the receptor complex 
[92].  A greater understanding of the non-canonical pathway may decipher an interesting therapeutic 
approach in β-catenin inhibition.  
Notch signalling 
Notch signalling is involved in a variety of cell-fate decisions that influence the development and 
function of many organs, including stem cell maintenance, cell proliferation, haemopoiesis and 
apoptosis [93, 94].  
Its role in malignancy has been shown to be cell and tissue-dependent, with the pathway playing both 
oncogenic and tumour suppressive roles depending on cell and cancer type [95-98]. In haemopoietic 
malignancies, accumulating evidence demonstrates its importance in growth, differentiation, and 
apoptosis [96, 97, 99-102], with its role in T-ALL, chronic lymphocytic leukaemia (CLL), and B cell 
leukaemias and lymphomas well documented [100, 101, 103, 104]. Improved understanding of the 
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Notch signalling pathway in these malignancies suggests that the Notch pathway may be a prime drug 
target; however, the therapeutic role of Notch inhibition may be directly dictated by the effects of its 
inhibition on other cell lineages, including the myeloid lineage [105, 106]. 
Reports about the role which Notch plays in myeloid disease are conflicting, as Notch activation in 
myeloid precursors has been shown to promote self-renewal, induce and inhibit differentiation to 
monocytes, or induce apoptosis [107-110].  Early observations suggested that Notch signalling may 
play a role in myeloid progression [110-112], with its role best characterised within AML. Importantly, 
it has been shown that exposing AML cells to plate-bound Notch ligands led to a full range of responses 
from proliferation to growth arrest that varied with patient sample, suggesting again the difficultly 
evaluating signalling pathways due to inter-patient heterogeneity [113]. More recently, observations 
have supported a tumour suppressive role for Notch signalling in immature LSC compartments of AML 
disease models [113-117]. Furthermore, in AML cell lines and primary patient blasts, downregulation 
of Notch1 expression was associated with a decrease in PU.1-mediated differentiation capacity, 
indicating a pivotal role in maintenance of an immature state [114].  
Within CML, the data is limited. In another myeloproliferative disorder, chronic myelomonocytic 
leukaemia, a tumour suppressor role for the Notch pathway was again described, supporting a loss-
of-function hypothesis [116]. Conversely, however, a recent paper has identified an antagonistic role 
between Notch and TKIs within primitive samples; although the mechanisms have not been fully 
elicited, this perhaps is representative of cross-talk between signalling pathways [118].  Recent data 
from our group has suggested the importance of Notch activation within LTC-IC assays, where 
activation of the CD34+38- population through Jagged1 led to a statistically significant reduction in 
colonies [119].  It remains to be seen if this pathway has a functional and, indeed, therapeutic role, 
within CML biology.  There are no clinical trials underway evaluating Notch modulation in myeloid 
disease. 
BMP signalling  
The bone morphogenic proteins (BMPs) belong to the transforming growth factor-beta (TGF-β) 
superfamily and have been shown to be involved in diverse cellular functions, from apoptosis to self-
renewal, in embryonic and adult phenotypes.  Dysregulation within the BMP-TGF-β pathway is critical 
in LSC survival [120-122], particularly mediated by its downstream target genes in the Cdx-Hox axis.   
 
Interaction between Wnt and BMP signalling regulate the Cdx family of homeobox transcription 
factors – the master regulators of Hox gene expression [123].  Cdx2 is aberrantly expressed in AML 
and promotes leukaemia propagation through deregulation of Hox genes [124], with its 
overexpression demonstrated in 90% of AML patients and overexpression in vivo leading to increased 
engraftment in NSG murine models.   Aberrant expression of HOX genes has been linked to both AML 
and CML [124, 125], with overexpression of HoxB3 [126], HoxB8 [127], or HoxA10 [126] leading to the 
generation of acute leukaemia in murine models, as well as being associated with expansion of the 
HSC compartment in in vitro and in vivo models [128, 129].  Although this represents an interesting 
target of both Wnt and BMP, no translational evidence is available for an antagonistic effect in LSC 
regression.  
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Genomic studies within primary CD34+ CML samples suggest that components of the pathway, 
including target genes, are downregulated [31, 130, 131]. This raises the possibility that the pathway 
can be activated through extrinsic mechanisms, and emphasises the role of the bone marrow 
microenvironment in the protection of LSCs against TKI-mediated apoptosis.   It has been shown that 
type 1 receptors are present on LSCs in primary CML samples, with an associated downregulation of 
BMP ligands [120, 131]. CML aspirate and trephine bone marrow samples had significantly higher 
levels of BMP2 and BMP4 compared to normal donors. This suggests that there is the ability to 
upregulate the BMP pathway and that it is via extrinsic mechanisms within the diseased bone marrow 
microenvironment/niche.  Laperrousaz et al [120] demonstrated that expression of BMP2 and BMP4 
varied depending on niche cell type, with BMP2 and BMP4 being more highly expressed in 
polymorphonuclear cells and endothelial sinusoid cells, respectively.  In response to increased levels 
of soluble BMP2 and BMP4, they showed that CML LSCs maintained their primitive phenotypes and 
enhanced long-term colony formation potential, indicating that the BMP pathway can suppress 
differentiation and potentiate LSC survival. 
 
The Bone Marrow Microenvironment 
Because LSCs home to the bone marrow microenvironment, it seems pertinent that the bone marrow 
is considered within cell-to-cell interactions and activation of aberrant self-renewal signalling.  The 
interactions between LSCs and the bone marrow remain an important area of research and may 
determine the best strategy for eradication of the LSC.  In many myeloid leukaemias’ there is enhanced 
osteoblastic proliferation and a marked increase in LSCs and progenitor expansion [132].  LSCs rely on 
the bone marrow niche for their survival and modulate it to enhance survival, and a number of key 
interactions with self-renewal pathways contribute to the chemo-resistance that is seen.  
Deregulation of BMP has been shown in murine models where Bmpr1a/Alk3 conditional knockout 
mice have impaired BMP signaling, which leads to increased niche size and thereby enhanced numbers 
of HSCs [133].  Furthermore, a number of ligand-receptor mediated pathways regulate CML LSC, and 
in turn alter signaling pathways responsible for their maintenance, including MPL which regulates 
JAK/STAT signaling [134].  MPL has been shown in high levels to lead to reduced TKI sensitivity in CML, 
although, in turn, a higher sensitivity to JAK inhibitors.  Expansion of the osteoblast layer of the CML 
bone marrow microenvironment can contribute to creating a hostile environment for HSC, mediated 
through alterations in TGFβ, NOTCH and pro-inflammatory signalling [132, 135].  However, there are 
difficulties in utilising the bone marrow microenvironment therapeutically – how should the pathways 
within the marrow be targeted? Would peripheral injections suffice to a large enough concentration 
of blockade without leading to adverse effects?  
 
4. Conclusion 
Aberrant signalling proteins have been extensively identified and evaluated within LSC biology. These 
represent a smaller number of signalling pathways.  Preclinical data suggests that targeting these 
unifying pathways may offer an attractive, and more broadly applicable, therapeutic strategy to 
eradicate the LSC compared to chemotherapy alone.  However, these signalling pathway interactions 
make them inherently complex, and modulating one may down- or up-regulate another, with 
biologically significant consequences.  Furthermore, there is limited understanding of the biology of 
the LSC following treatment, whether that be with systemic or targeted chemotherapy, with most 
preclinical studies utilising treatment-naïve patient samples, or murine models.  Further work is 
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needed to understand these intricacies.   With increased scientific understanding, the next question 
will relate to translating these targets from bench to bedside, and with this many questions will unfold.  
 
5. Expert Opinion: 
The above suggests that as LSCs retain dependency on self-renewal pathways, they could be 
selectively targeted if the complexities in their interactions are fully understood.  Disappointingly, 
despite strong in vitro and in vivo preclinical data, drugs against these targets have yet to be 
implemented in the clinical setting as a standard of care.  This is, in part, due to trial design, as well as 
toxicities that are generated, particularly in areas with high cell turnover, such as the gastrointestinal 
tract. 
 
The clinical need for alternative and more effective therapies in AML and CML are different.   AML 
represents a disease where there has been little progress in therapeutic strategies, with improvement 
in survival likely secondary to better supportive measurements rather than improvements in standard 
chemotherapeutics.  The need for targeted and individualised treatments is a necessity in the disease 
for improved outcome and eventual cure.  However, the targeting of LSCs is likely only to be effective 
in a minority of patients and will vary, dependent on the sub-class of disease.  The difficulty remains 
in 1) identification of LSC in bulk samples with no established immunophenotype, and 2) 
understanding the differences in signalling pathways within an epigenetic, genetic, and 
morphologically heterogeneous disease. 
Within CML, there has been an overall improvement in survival of approximately ten-fold since the 
introduction of targeted therapy against BCR-ABL [136].  This has led to the majority of patients 
achieving close to normal life expectancy, when treated with TKIs.  The need for eradication of the LSC 
is necessary to enable complete eradication of CML and subsequent cure, allowing patients to stop 
therapy, and to alleviate a financial burden within healthcare systems.  Like AML, a biomarker of the 
LSC needs to be identified and sensitive enough to identify CML LSCs at low level following treatment.  
A number of potential biomarkers have been described, including CD26 [137], and IL1-RAP [138].   Our 
group has described the role of CD93 as a potential biomarker of the quiescent LSC population within 
CML [139].  Although identification of the CML LSC appears to be within reach, little is known about 
the biology of the LSC in those patients that are in deep molecular response, with much of our 
understanding and the previous data within a drug-naïve population.  Clinically, the therapeutic need 
will be in those that are on TKI therapy.   
The biological understanding of aberrant self-renewal pathways within the LSC and potential targets 
is well underway, however the preparation for translation into the clinical setting needs to be 
considered.  Firstly, as stated above, within each disease the immunophenotypic characterisation of 
the LSC needs to be established.  When this is verified and supported internationally, there are 
considerations that need to be addressed to translate targeted inhibition or activation clinically. 
Firstly, decisions regarding evaluation of response to self-renewal modulation.  Within an in vivo and 
in vitro setting, these responses are often generated by utilising immature populations of sorted cells 
or genetically manipulating murine models.  Within a clinical setting, the response of bulk disease 
cannot be used as a surrogate for the clinical effect on the LSC population as there are differential 
sensitivities between the bulk and LSC populations, nor can evaluation of survival be used as a 
surrogate in treatment evaluation.  Clearly, established markers of the LSC (e.g. murine engraftment, 
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LTC-IC assessment, replating efficiency) may be used as a surrogate for response, or an MRD 
evaluation could be used to generate some understanding of the proportion of LSC at diagnosis and 
then following treatment.    
Secondly, comparing new targeted approaches to standardised chemotherapy regimens needs to be 
carefully executed.  The use of gemtuzumab ozogamicin in AML has directed understanding of the 
evaluation of a targeted response compared to standard treatments [140, 141], with a realisation that 
often a targeted therapeutic approach within bulk samples will require a longer treatment period to 
achieve a clinical response.  Can overall survival be used as an endpoint if standard chemotherapy 
eradicates bulk disease, whereas targeted approaches are acting as an adjunctive therapy that 
requires longer duration to see an effect? 
Thirdly, treatment timings of intervention will be essential in the understanding of disease biology.  
The treatments could be started simultaneously to allow for the likely longer duration needed for the 
targeted therapy to achieve a response.  But this would cause difficulties in an appropriate primary 
clinical end-point and evaluation of the LSC response to therapy.  Alternatively, the treatments could 
be sequenced to allow for identification of those patients, particularly with CML, where targeted 
therapy is not needed, and in AML, in those that have MRD positivity despite chemotherapy.  This 
would, however, open the potential for clonal evolution of the disease, that may render it more 
difficult to treat and skew results of an LSC-targeted approach.  With a concurrent approach, it is likely 
that drug toxicities may be a clinical issue, rendering the approach undeliverable as a standard-of-
care.  
 
Therefore, not only is an in-depth understanding of aberrant signalling pathway biology within LSCs 
required for generation of appropriate and justifiable therapeutic targets in the eradication of LSCs, 
careful consideration in the isolation and identification of LSCs, endpoint response, and timing of 
therapy is needed to enable translation of the therapeutic targets into a clinical setting.  
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Figure Legends 
 
Figure 1. Complex interactions between self-renewal pathways.  The interconnectivity between 
self-renewal pathways is well documented within the LSC.  It is known that proteins within 
each of the pathways, namely hedgehog, Wnt, and Notch, can both antagonise and agonise 
the other pathways by cross talk leading to both up- and downregulation of downstream 
targets.  
 
 
REFERENCES 
 
1. Alison MR, Lim SML, Nicholson LJ. Cancer stem cells: problems for therapy? Journal 
of Pathology. 2011;223(2):147-61. 
2. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. 
Nature. 2001;414(6859):105-11. 
3. Busfield SJ, Biondo M, Wong M, et al. Targeting of acute myeloid leukemia in vitro 
and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 
2014;28(11):2213-21. 
4. Crews LA, Jamieson CHM. Chronic Myeloid Leukemia Stem Cell Biology. Current 
Hematologic Malignancy Reports. 2012;7(2):125-32. 
5. Zhang B, Li M, McDonald T, et al. Microenvironmental protection of CML stem and 
progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin 
signaling. Blood. 2013;121(10):1824-38. 
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-7. 
7. Graham SM, Vass JK, Holyoake TL, et al. Transcriptional analysis of quiescent and 
proliferating CD34+human hemopoietic cells from normal and chronic myeloid leukemia 
sources. Stem Cells. 2007;25(12):3111-20. 
8. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: A 
model for studying the biology and treatment of myeloma and its manifestations. Blood. 
1998;92(8):2908-13. 
9. Bhatia M, Wang JCY, Kapp U, et al. Purification of primitive human hematopoietic 
cells capable of repopulating immune-deficient mice. Proceedings of the National Academy 
of Sciences of the United States of America. 1997;94(10):5320-5. 
10. Jordan CT, Guzman ML, Noble M. Mechanisms of disease - Cancer stem cells. New 
England Journal of Medicine. 2006;355(12):1253-61. 
11. Lapidot T, Sirard C, Vormoor J, et al. A Cell Initiating Human Acute Myeloid-Leukemia 
after Transplantation into Scid Mice. Nature. 1994;367(6464):645-8. 
12. Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute 
myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 
1997;89(9):3104-12. 
13. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with 
long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-
DR-. Blood. 1998;92(11):4325-35. 
12 
 
14. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a 
unique marker for human acute myelogenous leukemia stem cells. Leukemia. 
2000;14(10):1777-84. 
15. Sarry JE, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are 
rare and heterogeneous when assayed in NOD/SCID/IL2R gamma c-deficient mice. Journal 
of Clinical Investigation. 2011;121(1):384-95. 
16. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some 
acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) 
fraction. Blood. 2010;115(10):1976-84. 
17. Al-Mawali A, Gillis D, Lewis I. Immunoprofiling of leukemic stem cells CD34+/CD38-
/CD123+delineate FLT3/ITD-positive clones. Journal of Hematology & Oncology. 2016;9. 
18. Ehninger A, Kramer M, Rollig C, et al. Distribution and levels of cell surface 
expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer Journal. 2014;4. 
19. Kersten B, Valkering M, Wouters R, et al. CD45RA, a specific marker for leukaemia 
stem cell sub-populations in acute myeloid leukaemia. British Journal of Haematology. 
2016;173(2):219-35. 
20. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and 
therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 
2009;138(2):286-99. 
21. Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in 
human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the 
United States of America. 2007;104(26):11008-13. 
22. Iwasaki M, Liedtke M, Gentles AJ, et al. CD93 Marks a Non-Quiescent Human 
Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute 
Myeloid Leukemia. Cell Stem Cell. 2015;17(4):412-21. 
23. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs 
influence clinical outcome in human leukemia. Nature Medicine. 2011;17(9):1086-U91. 
24. Mendler JH, Balys M, Sivagnanalingam U, et al. Distinct Properties of Leukemia Stem 
Cells in Primary Refractory Acute Myeloid Leukemia. Blood. 2015;126(23). 
25. van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on 
the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the 
malignant from the normal stem cell compartment both at diagnosis and in remission. 
Leukemia. 2007;21(8):1700-7. 
26. Feller N, van der Pol MA, van Stijn A, et al. MRD parameters using 
immunophenotypic detection methods are highly reliable in predicting survival in acute 
myeloid leukaemia. Leukemia. 2004;18(8):1380-90. 
27. Ivey A, Hills RK, Simpson MA, et al. Assessment of Minimal Residual Disease in 
Standard-Risk AML. New England Journal of Medicine. 2016;374(5):422-33. 
28. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid 
leukemia at diagnosis predicts high minimal residual disease and poor survival. Clinical 
Cancer Research. 2005;11(18):6520-7. 
29. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as 
candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-67. 
30. Kinstrie R, Karamitros D, Goardon N, et al. Heterogeneous leukemia stem cells in 
myeloid blast phase chronic myeloid leukemia. Blood Advances. 2016;1(3):160-9. 
31. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression 
and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794-9. 
13 
 
32. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in 
chronic myelogenous leukemia patients in complete cytogenetic remission following 
imatinib mesylate treatment. Blood. 2003;101(12):4701-7. 
33. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic 
myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 
2011;118(13):3657-60. 
34. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic 
myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors 
and the impact of therapy discontinuation. Oncotarget. 2016;7(23):35293-301. 
35. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic 
myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 
2011;118(20):5565-72. 
36. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells 
are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 
2011;121(1):396-409. 
37. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells 
are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501-10. 
38. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic 
myeloid leukaemia who have maintained complete molecular remission for at least 2 years: 
the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35. 
39. Richter J, Mahon FX, Guilhot J, et al. Stopping Tyrosine Kinase Inhibitors in a Very 
Large Cohort of European Chronic Myeloid Leukemia Patients: Results of the Euro-Ski Trial. 
Haematologica. 2016;101:22-3. 
40. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for 
CML patients with stable undetectable minimal residual disease: results from the TWISTER 
study. Blood. 2013;122(4):515-22. 
41. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients 
with chronic myeloid leukemia. Haematologica-the Hematology Journal. 2012;97(6):903-6. 
42. Etienne G, Guilhot J, Rea D, et al. Long-Term Follow-Up of the French Stop Imatinib 
(STIM1) Study in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology. 
2017;35(3):298-+. 
43. Liao HF, Su YC, Zheng ZY, et al. Sonic hedgehog signaling regulates Bcr-Abl expression 
in human chronic myeloid leukemia cells. Biomedicine & Pharmacotherapy. 2012;66(5):378-
83. 
44. Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the 
phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in 
normal myelopoiesis and leukemogenesis. Biochimica Et Biophysica Acta-Molecular Cell 
Research. 2010;1803(9):991-1002. 
45. Naughton R, Quiney C, Turner SD, et al. Bcr-Abl-mediated redox regulation of the 
PI3K/AKT pathway. Leukemia. 2009;23(8):1432-40. 
46. Sengupta A, Banerjee D, Chandra S, et al. Deregulation and cross talk among Sonic 
hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. 
Leukemia. 2007;21(5):949-55. 
47. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and 
CML stem cells in vivo. Cancer Cell. 2007;12(6):528-41. 
14 
 
48. Somervaille TCP, Matheny CJ, Spencer GJ, et al. Hierarchical Maintenance of MLL 
Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic 
Rather Than Adult Stem Cells. Cell Stem Cell. 2009;4(2):129-40. 
49. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly 
patients with acute myeloid leukemia. Blood. 2001;97(11):3589-95. 
50. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is 
dependent on Hedgehog pathway activation. Cancer Cell. 2008;14(3):238-49. 
51. Long B, Zhu H, Zhu C, et al. Activation of the Hedgehog pathway in chronic 
myelogeneous leukemia patients. J Exp Clin Cancer Res. 2011;30:8. 
52. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance 
of cancer stem cells in myeloid leukaemia. Nature. 2009;458(7239):776-9. 
53. Hui CC, Angers S. Gli Proteins in Development and Disease. Annual Review of Cell 
and Developmental Biology, Vol 27. 2011;27:513-37. 
54. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic 
hedgehog. Nature Reviews Genetics. 2006;7(11):841-50. 
55. Campbell VL, Tarafdar A, Dobbin E, et al. Unravelling the complexities of hedgehog 
mediated signal transduction in acute myeloid leukaemia and normal haematopoiesis. 
Blood. 2016;128:2881. 
56. Singh M, Chaudhry P, Merchant AA. Primary cilia are present on human blood and 
bone marrow cells and mediate Hedgehog signaling. Experimental Hematology. 
2016;44(12):1181-7. 
57. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 
2012;119(10):2196-204. 
58. Irvine DA, Zhang B, Kinstrie R, et al. Deregulated hedgehog pathway signaling is 
inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic 
myeloid leukaemia. Scientific Reports. 2016;6:25476. 
59. Martinelli G, Oehler VG, Papayannidis C, et al. Treatment with PF-04449913, an oral 
smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and 
pharmacokinetics study. Lancet Haematology. 2015;2(8):E339-E46. 
60. Su W, Meng F, Huang L, et al. Sonic hedgehog maintains survival and growth of 
chronic myeloid leukemia progenitor cells through beta-catenin signaling. Exp Hematol. 
2012;40(5):418-27. 
61. Colaluca IN, Tosoni D, Nuciforo P, et al. NUMB controls p53 tumour suppressor 
activity. Nature. 2008;451(7174):76-U11. 
62. Sheng WW, Dong M, Zhou JP, et al. Cooperation among Numb, MDM2 and p53 in 
the development and progression of pancreatic cancer. Cell and Tissue Research. 
2013;354(2):521-32. 
63. Abraham SA, Hopcroft LEM, Carrick E, et al. Dual targeting of p53 and c-MYC 
selectively eliminates leukaemic stem cells. Nature. 2016;534(7607):341- 6. 
64. Latif AL, Cole JJ, Campos JM, et al. Dual Inhibition of MDM2 and BET Cooperate to 
Eradicate Acute Myeloid Leukemia. Blood. 2015;126(23):674. 
65. Sadarangani A, Pineda G, Lennon KM, et al. GLI2 inhibition abrogates human 
leukemia stem cell dormancy. J Transl Med. 2015;13:98. 
66. Rudin CM, Hann CL, Laterra J, et al. Brief Report: Treatment of Medulloblastoma 
with Hedgehog Pathway Inhibitor GDC-0449. New England Journal of Medicine. 
2009;361(12):1173-8. 
15 
 
67. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the Hedgehog Pathway in 
Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 2009;361(12):1164-72. 
68. Ottmann O, Charbonnier A, Stegelmann F, et al. Smoothened (Smo) Inhibitor Lde225 
Combined with Nilotinib in Patients with Chronic Myeloid Leukemia (Cml) 
Resistant/Intolerant (R/I) to at Least 1 Prior Tyrosine Kinase Inhibitor: A Phase 1b Study. 
Haematologica. 2015;100:62-3. 
69. Shah NP, Cortes JE, Martinelli G, et al. Dasatinib Plus Smoothened (SMO) Inhibitor 
BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to 
a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323. Blood. 2014;124(21). 
70. Bai LY, Chiu CF, Lin CW, et al. Differential expression of Sonic hedgehog and Gli1 in 
hematological malignancies. Leukemia. 2008;22(1):226-8. 
71. Yang DG, Cao FL, Ye XM, et al. Arsenic Trioxide Inhibits the Hedgehog Pathway Which 
Is Aberrantly Activated in Acute Promyelocytic Leukemia. Acta Haematologica. 
2013;130(4):260-7. 
72. Wellbrock J, Latuske E, Kohler J, et al. Expression of Hedgehog Pathway Mediator GLI 
Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its 
Inhibition Exerts Antileukemic Effects. Clin Cancer Res. 2015;21(10):2388-98. 
73. Kobune M, Iyama S, Kikuchi S, et al. Stromal cells expressing hedgehog-interacting 
protein regulate the proliferation of myeloid neoplasms. Blood Cancer J. 2012;2:e87. 
74. Hofmann I, Stover EH, Cullen DE, et al. Hedgehog Signaling Is Dispensable for Adult 
Murine Hematopoietic Stem Cell Function and Hematopoiesis. Cell Stem Cell. 2009;4(6):559-
67. 
75. Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor 
attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Science. 
2016;107(10):1422-9. 
76. Cortes J, Heidel FH, Heuser M, et al. A phase 2 randomized study of low dose ara-C 
with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia 
ir high-risk myelodysplastic syndrome. Blood. 2016;128:99. 
77. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 
2006;127(3):469-80. 
78. Ho TC, LaMere M, Stevens BM, et al. Evolution of acute myelogenous leukemia stem 
cell properties after treatment and progression. Blood. 2016;128(13):1671-8. 
79. Heidel FH, Bullinger L, Feng ZH, et al. Genetic and Pharmacologic Inhibition of beta-
Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell. 
2012;10(4):412-24. 
80. Gang EJ, Hsieh YT, Pham J, et al. Small-molecule inhibition of CBP/catenin 
interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 
2014;33(17):2169-78. 
81. Zhao Y, Masiello D, McMillian M, et al. CBP/catenin antagonist safely eliminates 
drug-resistant leukemia-initiating cells. Oncogene. 2016;35(28):3705-17. 
82. Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute myeloid 
leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 
2006;20(7):1211-6. 
83. Wang YZ, Krivtsov AV, Sinha AU, et al. The Wnt/beta-Catenin Pathway Is Required for 
the Development of Leukemia Stem Cells in AML. Science. 2010;327(5973):1650-3. 
84. Yeung J, Esposito MT, Gandillet A, et al. beta-Catenin Mediates the Establishment 
and Drug Resistance of MLL Leukemic Stem Cells. Cancer Cell. 2010;18(6):606-18. 
16 
 
85. Goessling W, North TE, Loewer S, et al. Genetic Interaction of PGE2 and Wnt 
Signaling Regulates Developmental Specification of Stem Cells and Regeneration. Cell. 
2009;136(6):1136-47. 
86. Cortes JE, Carter BZ, Quintas-Cardama A, et al. A Phase I Dose-Escalation Study of Pri-
724, a Cbp/B-Catenin Modulator in Patients with Advanced Acute Myeloid Leukemia (Aml). 
Haematologica. 2014;99:222-3. 
87. Riether C, Schurch CM, Flury C, et al. Tyrosine kinase inhibitor-induced CD70 
expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. 
Science Translational Medicine. 2015;7(298). 
88. Schurch C, Riether C, Matter MS, et al. CD27 signaling on chronic myelogenous 
leukemia stem cells activates Wnt target genes and promotes disease progression. Journal 
of Clinical Investigation. 2012;122(2):624-38. 
89. Kode A, Manavalan JS, Mosialou I, et al. Leukaemogenesis induced by an activating 
beta-catenin mutation in osteoblasts. Nature. 2014;506(7487):240-+. 
90. Ford CE, Ma SSQ, Quadir A, et al. The dual role of the novel Wnt receptor tyrosine 
kinase, ROR2, in human carcinogenesis. International Journal of Cancer. 2013;133(4):779-
87. 
91. Shen YL, Luo Q, Guo YX, et al. Bone marrow mesenchymal stem cell-derived Wnt5a 
inhibits leukemia cell progression in vitro via activation of the non-canonical Wnt signaling 
pathway. Oncology Letters. 2014;8(1):85-90. 
92. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. 
Nature Reviews Cancer. 2013;13(1):11-26. 
93. Chiba S. Notch signaling in stem cell systems. Stem Cells. 2006;24(11):2437-47. 
94. Bray SJ. Notch signalling in context. Nature Reviews Molecular Cell Biology. 
2016;17(11):722-35. 
95. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor 
survival. Carcinogenesis. 2013;34(7):1420-30. 
96. Pancewicz J, Nicot C. Current views on the role of Notch signaling and the 
pathogenesis of human leukemia. Bmc Cancer. 2011;11. 
97. Schwanbeck R, Just U. The Notch signaling pathway in hematopoiesis and 
hematologic malignancies. Haematologica-the Hematology Journal. 2011;96(12):1735-U21. 
98. Yugaw T, Nishino K, Ohno SI, et al. Noncanonical NOTCH Signaling Limits Self-
Renewal of Human Epithelial and Induced Pluripotent Stem Cells through ROCK Activation. 
Molecular and Cellular Biology. 2013;33(22):4434-47. 
99. Chiang MY, Shestova O, Xu LW, et al. Divergent effects of supraphysiologic Notch 
signals on leukemia stem cells and hematopoietic stem cells. Blood. 2013;121(6):905-17. 
100. Etet PFS, Vecchio L, Kamdje AHN. Interactions between bone marrow stromal 
microenvironment and B-chronic lymphocytic leukemia cells: Any role for Notch, Wnt and 
Hh signaling pathways? Cellular Signalling. 2012;24(7):1433-43. 
101. Hannon MM, Lohan F, Erbilgin Y, et al. Elevated TRIB2 with NOTCH1 activation in 
paediatric/adult T-ALL. British Journal of Haematology. 2012;158(5):626-34. 
102. Kamdje AHN, Mosna F, Bifari F, et al. Notch-3 and Notch-4 signaling rescue from 
apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal 
stromal cells. Blood. 2011;118(2):380-9. 
103. Ellisen LW, Bird J, West DC, et al. Tan-1, the Human Homolog of the Drosophila 
Notch Gene, Is Broken by Chromosomal Translocations in T-Lymphoblastic Neoplasms. Cell. 
1991;66(4):649-61. 
17 
 
104. Kamdje AHN, Krampera M. Notch signaling in acute lymphoblastic leukemia: any role 
for stromal microenvironment? Blood. 2011;118(25):6506-14. 
105. Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch 
inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) 
and other leukemias. Journal of Clinical Oncology. 2006;24(18):357s-s. 
106. Krop I, Demuth T, Guthrie T, et al. Phase I Pharmacologic and Pharmacodynamic 
Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced 
Solid Tumors. Journal of Clinical Oncology. 2012;30(19):2307-13. 
107. Carlesso N, Aster JC, Sklar J, et al. Notch1-induced delay of human hematopoietic 
progenitor cell differentiation is associated with altered cell cycle kinetics. Blood. 
1999;93(3):838-48. 
108. Li LH, Milner LA, Deng Y, et al. The human homolog of rat Jagged1 expressed by 
marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. 
Immunity. 1998;8(1):43-55. 
109. Sarmento LM, Huang H, Limon A, et al. Notch1 modulates timing of G(1)-S 
progression by inducing SKP2 transcription and p27(Kip1) degradation. Journal of 
Experimental Medicine. 2005;202(1):157-68. 
110. Schroeder T, Kohlhof H, Rieber N, et al. Notch signaling induces multilineage myeloid 
differentiation and up-regulates PU.1 expression. Journal of Immunology. 
2003;170(11):5538-48. 
111. Milner LA, Bigas A, Kopan R, et al. Inhibition of granulocytic differentiation by 
mNotch1. Proceedings of the National Academy of Sciences of the United States of America. 
1996;93(23):13014-9. 
112. Tan-Pertel HT, Walker L, Browning D, et al. Notch signaling enhances survival and 
alters differentiation of 32D myeloblasts. Journal of Immunology. 2000;165(8):4428-36. 
113. Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid 
leukemia cells. Leukemia & Lymphoma. 2001;42(3):467-72. 
114. Chen PM, Yen CC, Wang WS, et al. Down-regulation of Notch-1 expression decreases 
PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia. International 
Journal of Oncology. 2008;32(6):1335-41. 
115. Kannan S, Sutphin RM, Hall MG, et al. Notch activation inhibits AML growth and 
survival: a potential therapeutic approach. Journal of Experimental Medicine. 
2013;210(2):321-37. 
116. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for 
the Notch pathway in myeloid leukaemia. Nature. 2011;473(7346):230-+. 
117. Lobry C, Ntziachristos P, Ndiaye-Lobry D, et al. Notch pathway activation targets 
AML-initiating cell homeostasis and differentiation. Journal of Experimental Medicine. 
2013;210(2):301-19. 
118. Aljedai A, Buckle AM, Hiwarkar P, et al. Potential Role of Notch Signalling in CD34(+) 
Chronic Myeloid Leukaemia Cells: Cross-Talk between Notch and BCR-ABL. Plos One. 
2015;10(4). 
119. Horne GA, Morrison H, Campbell VL, et al. Notch Pathway Activation Targets 
Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). Blood. 
2016;128:3057. 
120. Laperrousaz B, Jeanpierre S, Sagorny K, et al. Primitive CML cell expansion relies on 
abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood. 
2013;122(23):3767-77. 
18 
 
121. Miyanari Y, Torres-Padilla ME. Control of ground-state pluripotency by allelic 
regulation of Nanog. Nature. 2012;483(7390):470-U123. 
122. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-
initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676-U111. 
123. Lengerke C, Schmitt S, Bowman TV, et al. BMP and Wnt specify hematopoietic fate 
by activation of the Cdx-Hox pathway. Cell Stem Cell. 2008;2(1):72-82. 
124. Scholl C, Bansal D, Dohner K, et al. The homeobox gene CDX2 is aberrantly expressed 
in most cases of acute myeloid leukemia and promotes leukemogenesis. Journal of Clinical 
Investigation. 2007;117(4):1037-48. 
125. Grier DG, Thompson A, Kwasniewska A, et al. The pathophysiology of HOX genes and 
their role in cancer. Journal of Pathology. 2005;205(2):154-71. 
126. Sauvageau G, Thorsteinsdottir U, Hough MR, et al. Overexpression of HOXB3 in 
hematopoietic cells causes defective lymphoid development and progressive 
myeloproliferation. Immunity. 1997;6(1):13-22. 
127. Perkins A, Kongsuwan K, Visvader J, et al. Homeobox Gene-Expression Plus Autocrine 
Growth-Factor Production Elicits Myeloid-Leukemia. Proceedings of the National Academy 
of Sciences of the United States of America. 1990;87(21):8398-402. 
128. Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult 
hematopoietic stem cells ex vivo. Cell. 2002;109(1):39-45. 
129. Thorsteinsdottir U, Mamo A, Kroon E, et al. Overexpression. of the myeloid 
leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 
2002;99(1):121-9. 
130. Gerber JM, Gucwa JL, Esopi D, et al. Genome-wide comparison of the transcriptomes 
of highly enriched normal and chronic myeloid leukemia stem and progenitor cell 
populations. Oncotarget. 2013;4(5):715-28. 
131. Toofan P, Irvine D, Hopcroft L, et al. The role of the bone morphogenetic proteins in 
leukaemic stem cell persistence. Biochemical Society Transactions. 2014;42:809-15. 
132. Krause DS, Fulzele K, Catic A, et al. Differential regulation of myeloid leukemias by 
the bone marrow microenvironment. Nature Medicine. 2013;19(11):1513-+. 
133. Zhang JW, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and 
control of the niche size. Nature. 2003;425(6960):836-41. 
134. Zhang B, Li L, Ho YW, et al. Heterogeneity of leukemia-initiating capacity of chronic 
myelogenous leukemia stem cells. Journal of Clinical Investigation. 2016;126(3):975-91. 
135. Bowers M, Zhang B, Ho YW, et al. Osteoblast ablation reduces normal long-term 
hematopoietic stem cell self-renewal but accelerates leukemia development. Blood. 
2015;125(17):2678-88. 
136. Bower H, Bjorkholm M, Dickman PW, et al. Life Expectancy of Patients With Chronic 
Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 
2016;34(24):2851-7. 
137. Herrmann H, Sadovnik I, Cerny-Reiterer S, et al. Dipeptidylpeptidase IV (CD26) 
defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123(25):3951-62. 
138. Landberg N, Hansen N, Askmyr M, et al. IL1RAP expression as a measure of leukemic 
stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. 
Leukemia. 2016;30(1):253-7. 
139. Kinstrie R, Horne GA, Morrison H, et al. CD93 Is a Novel Biomarker of Leukemia Stem 
Cells in Chronic Myeloid Leukemia. Blood. 2015;126(23). 
19 
 
140. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab 
ozogamicin during induction and postconsolidation therapy in younger patients with acute 
myeloid leukemia. Blood. 2013;121(24):4854-60. 
141. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a 
remarkable saga about an active drug. Blood. 2013;121(24):4838-41. 
 
 
Hh signalling
Notch signalling
Canonical Wnt
signalling
SMO
GLI1
Downstream 
target genes
HES1
JAG2
JAG1
DVL
GSK3
B-catenin
